Roluperidone for negative symptoms and relapse in schizophrenia
About this title
Read the official source — NCT07565428This study evaluates the effectiveness of Roluperidone for people with schizophrenia.
Understand this study
What is this study about?
This study evaluates the effectiveness of Roluperidone for people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
- Listed locations
- Bellflower and 12 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 380
- Sponsor
- Minerva Neurosciences
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07565428
- Official title
Show the full official title
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects With Schizophrenia, Followed by a 52-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Recruitment & locations
Bellflower · Culver City · Garden Grove
10 more locations
- Riverside
- Hallandale
- Hollywood
- Tampa
- Atlanta
- Decatur
- Gaithersburg
- Marlton
- New York
- Richardson
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the effectiveness of Roluperidone for people with schizophrenia.
Who is behind this study?
The study sponsor is Minerva Neurosciences.
Does this study involve medication?
Yes. The study involves medication, including Roluperidone, risperidone, aripiprazole, olanzapine and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
